ELVNEnliven Therapeutics Inc
ELVN
Enliven Therapeutics Inc1,244
Mkt Cap
$1.08BVolume
523,622.0052W High
$29.4052W Low
$13.30PE Ratio
-9.14ELVN Fundamentals
Price
$18.30Prev Close
$18.50Open
$18.3450D MA
$20.31Beta
1.42Avg. Volume
426,659.70EPS (Annual)
-$1.89P/B
2.22Rev/Employee
$0.00Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday
Enliven Therapeutics (NASDAQ:ELVN) will be releasing its Q3 2025 earnings before the market opens on Wednesday, November 12. (View Earnings Report at...
MarketBeat·17h ago
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 106.5% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
Enliven Therapeutics, Inc. (ELVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41%
The consensus price target hints at a 102.4% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·4mo ago
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference PR Newswire BOULDER, Colo., Feb...
PR Newswire·8mo ago
Mizuho refreshes its US top picks list for January
Investing.com -- Mizuho (NYSE:MFG) has updated its US Top Picks list for January, adding Chewy (NYSE:CHWY), GE Vernova (NYSE:GEV), Enliven Therapeutics Inc (NASDAQ:ELVN), Quest Diagnostics (NYSE:DGX), DuPont de Nemours (NYSE:DD), and Salesforce (NYSE:CRM). These selections reflect Mizuho’s highest-conviction ideas driven by catalysts expected to play out over the next 12 months.
investing.com·10mo ago
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update PR Newswire...
PR Newswire·1y ago
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference Enliven Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire BOULDER, Colo., Nov. 7, 2024...
PR Newswire·1y ago